Natco Pharma today said its co-development and marketing partner Dr Reddys Laboratories Ltd has filed an application with the European Medicines Agency for marketing a cancer drug in Europe.
In a press release here, Natco said the duxorubicinhydrochloride liposome injection, a therapeutic equivalent to the generic version of Jessens Doxil, is for intravenous use for treating metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma.
The Doxil brand of 2mg/ml had sales of approximately USD 130.5 million in Europe, for the 12 months ending December 31, 2017, Natco said citing market reports